NASDAQ$CBUS

Cibus Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Announced financial results for the quarter ended September 30, 2023, and provided a business update.

Cibus reported its Q3 2023 financial results, highlighting progress in commercializing its pod shatter reduction (PSR) trait in canola and winter oilseed rape (WOSR), as well as HT1 and HT3 traits in rice. The company is advancing its soybean single cell operating system and has seen positive developments in gene editing regulations.

  • Continued progress toward the commercialization of pod shatter reduction (PSR) trait in canola and winter oilseed rape (WOSR).
  • Continued progress toward the commercialization of HT1 and HT3 in rice, with a large increase in customer base in North and South America.
  • Continued progress in developing the Company's soybean single cell operating system, with key work expected in the fourth quarter of 2023.
  • Experienced continued positive developments in gene editing regulations, including approval in the UK and proposed regulations in the EU.

Headline financials

Total Revenue

$475K

Previous: $42K+1031.0%
EPS (adj)

-$1.59

Previous: -$0.65-144.6%
Capital Expenditures

-$3.87M

Previous: -$1.51M-156.6%
Free Cash Flow

-$30.3M

Previous: -$7.46M-306.2%
Net Income

-$26.4M

Previous: -$5.95M-344.2%
Operating Income

-$25.8M

Previous: -$6.2M-315.9%
Gross Profit

-$1.21M

Previous: $42K-2978.6%
Cash & Equivalents

$31.9M

Previous: $7.03M+353.5%
Total Assets

$796M

Previous: $26.7M+2881.9%
R&D Expense

$17.5M

No prior period
Stock-Based Comp

$5.83M

Previous: $1.04M+463.1%

Revenue & EPS history

Cibus · Revenue · Quarterly

$475K

Q3 2023+1,031%vs Q3 2022
Beat estimate in 5 of 14 quarters(36%)
ActualEstimate

Forward guidance

Cibus expects to enable regeneration of soybean plants from single cells in Q4 2023, with initial edits and improvements projected during 2024. They also plan to transfer their PSR trait in up to 4 additional elite germplasm of additional seed company customers and to gain additional rice customers for HT1 and HT3 in South America.

Tailwinds

  • Enabling regeneration of soybean plants from single cells is expected to be completed in the fourth quarter of 2023.
  • Initial edits and improvements of soybean system projected during 2024.
  • Transfer PSR trait in up to 4 additional elite germplasm of additional seed company customers.
  • Attract additional rice customers for HT1 and HT3 in South America.
  • Successful transfer of elite germplasm to Cibus from new rice customers.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

-1.1%

Avg return

Earnings day

-2.2%

Avg return

5 days after

-12.4%

Avg return

30 days after

37%

13 / 35 earnings

Positive

+23.6%

Q4 2019

Best reaction

-25.1%

Q4 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.8%-10.3%
Q4 2025-16.7%-24.7%-56.8%
Q3 2025-0.8%+1.6%+28.8%
Q2 2025-3.5%-11.6%-7.5%
Q1 2025-7.8%-8.1%-29.4%
Q4 2024-6.4%-9.6%-23.7%
Q3 2024+14.5%+15.2%-8.9%
Q2 2024-9.2%+2.7%-42.4%
Q1 2024+2.2%+9.5%-37.5%
Q4 2023-0.7%+2.2%+7.4%
Q3 2023+17.0%+5.0%-8.8%
Q2 2023-9.7%-13.8%-19.8%
Q1 2023-3.6%-8.3%-15.8%
Q4 2022+1.6%-0.7%-21.5%
Q3 2022-1.4%-7.7%+22.5%
Q2 2022+12.4%+4.3%-11.6%
Q1 2022-17.3%-27.4%-60.0%
Q4 2021-2.8%-21.3%-20.6%
Q3 2021-7.4%-9.0%-41.9%
Q2 2021+12.0%+15.1%+19.9%
Q1 2021+4.6%+3.3%-17.4%
Q4 2020-25.1%-24.7%-35.6%
Q3 2020-1.4%-4.0%-44.3%
Q2 2020-6.6%+0.2%-8.3%
Q1 2020-15.0%-9.4%+27.9%
Q4 2019+23.6%+22.7%-10.1%
Q3 2019-9.7%-10.2%-16.3%
Q2 2019+2.7%-13.1%-23.9%
Q1 2019-3.5%-6.7%-9.3%
Q4 2018+8.3%+20.0%+34.0%
Q3 2018-2.9%-4.9%-22.1%
Q2 2018-0.7%-3.1%-10.8%
Q1 2018+1.9%+22.1%+28.1%
Q4 2017+6.4%+18.8%+16.9%
Q3 2017+7.8%+8.2%-2.2%
Q2 2017
Q1 2017
Q4 2016
Q3 2016
Q2 2016
Q1 2016

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro